________________________________________

FORM 8-K

________________________________________

Date of Report (Date of earliest event reported): June 16, 2026

________________________________________

________________________________________

Registrant’s Telephone Number, Including Area Code: (855) 268-2822

________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the

registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act

of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition

period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. ☐

On June 16, 2026, GoodRx Holdings, Inc. (the “Company”) held its Annual Meeting of Stockholders. Holders of the

Company’s Class A common stock were entitled to one vote per share held as of the close of business on April 20, 2026 (the

“Record Date”) and holders of the Company’s Class B common stock were entitled to ten votes per share held as of the

Record Date. A total of 89,932,951 shares of the Company’s Class A common stock and 233,964,187 shares of the

Company’s Class B common stock were present in person or represented by proxy at the meeting, representing

approximately 99.4% of the combined voting power of the Company’s Class A and Class B common stock as of the Record

Date. The following are the final voting results for the proposals considered and voted upon at the meeting, each of which

were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April

29, 2026.

Item 1 — Election of three Class III directors for a term of office expiring on the date of the Annual Meeting of

Stockholders to be held in 2029 and until their respective successors have been duly elected and qualified or until their

respective earlier death, resignation or removal.

Item 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting

firm for the fiscal year ending December 31, 2026.

Item 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive

officers.

Based on the foregoing votes, the Company’s stockholders (i) elected Wendy Barnes, Ronald E. Bruehlman and

Gregory Mondre as Class III directors; (ii) ratified the appointment of KPMG LLP as the Company’s independent registered

public accounting firm for the fiscal year ending December 31, 2026; and (iii) approved, on an advisory (non-binding) basis,

the compensation of the Company’s named executive officers.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report

to be signed on its behalf by the undersigned hereunto duly authorized.